Form SCHEDULE 13G/A Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR

SCHEDULE 13G

CUSIP No.

1

Names of Reporting Persons

Thomas A. Satterfield, Jr.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 95,000.00
6	Shared Voting Power 880,000.00
7	Sole Dispositive Power 95,000.00
8	Shared Dispositive Power 880,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

975,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.6 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: *Based on (i) 11,304,697 shares of common stock of the issuer (the "Common Stock") outstanding as of May 12, 2026, as reported by the issuer in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 and (ii) the sale of an additional 1,454,175 shares of Common Stock as reported by the issuer in its Current Report on Form 8-K filed May 14, 2026.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Lantern Pharma Inc.

(b)

Address of issuer's principal executive offices:

1920 McKinney Avenue, 7th Floor, Dallas, TX 75201

Item 2.

(a)

Name of person filing:

Thomas A. Satterfield, Jr.

(b)

Address or principal business office or, if none, residence:

15 Colley Cove Drive Gulf Breeze, Florida 32561

(c)

Citizenship:

Incorporated by reference from Item 4 of the Cover Page.

(d)

Title of class of securities:

Common Stock, $0.0001 par value per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

Incorporated by reference from Item 9 of the Cover Page.

(b)

Percent of class:

Incorporated by reference from Item 11 of the Cover Page. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Incorporated by reference from Item 5 of the Cover Page.

(ii) Shared power to vote or to direct the vote:

Incorporated by reference from Item 6 of the Cover Page.

(iii) Sole power to dispose or to direct the disposition of:

Incorporated by reference from Item 7 of the Cover Page.

(iv) Shared power to dispose or to direct the disposition of:

Incorporated by reference from Item 8 of the Cover Page.

Item 5.

Ownership of 5 Percent or Less of a Class.

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 25,000 shares are held jointly with Rebecca S. Satterfield, Mr. Satterfield's spouse; 100,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 500,000 shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 250,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield. Additionally, Mr. Satterfield has limited power of attorney for voting and disposition purposes with respect to 5,000 shares held by Rebecca S. Satterfield.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Thomas A. Satterfield, Jr.

Signature:	/s/ Thomas A. Satterfield, Jr.
Name/Title:	Thomas A. Satterfield, Jr.
Date:	07/23/2026

Form SCHEDULE 13G/A Lantern Pharma Inc. Filed by: SATTERFIELD THOMAS A JR

You May Also Be Interested In

Create E-mail Alert Related Categories

Related Entities

Sign up for StreetInsider Free!

Free News Feed